Bessemer Group’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26K | Buy |
1,469
+991
| +207% | +$13.9K | ﹤0.01% | 1908 |
|
|
2026
Q1 | $5K | Buy |
478
+38
| +9% | +$417 | ﹤0.01% | 2234 |
|
|
2025
Q4 | $6K | Sell |
440
-55
| -11% | -$731 | ﹤0.01% | 2223 |
|
|
2025
Q3 | $7K | Sell |
495
-1
| -0.2% | -$14 | ﹤0.01% | 2057 |
|
|
2025
Q2 | $6K | Sell |
496
-364
| -42% | -$5.29K | ﹤0.01% | 1971 |
|
|
2025
Q1 | $19K | Buy |
860
+6
| +0.7% | +$141 | ﹤0.01% | 1559 |
|
|
2024
Q4 | $19K | Sell |
854
-2,385
| -74% | -$52.1K | ﹤0.01% | 1537 |
|
|
2024
Q3 | $59K | Sell |
3,239
-1,303
| -29% | -$30.2K | ﹤0.01% | 1361 |
|
|
2024
Q2 | $132K | Sell |
4,542
-34,735
| -88% | -$1.03M | ﹤0.01% | 1101 |
|
|
2024
Q1 | $1.39M | Sell |
39,277
-4,505
| -10% | -$180K | ﹤0.01% | 615 |
|
|
2023
Q4 | $1.91M | Buy |
43,782
+8,442
| +24% | +$332K | ﹤0.01% | 489 |
|
|
2023
Q3 | $1.35M | Buy |
35,340
+9,750
| +38% | +$410K | ﹤0.01% | 553 |
|
|
2023
Q2 | $1.05M | Buy |
25,590
+13,604
| +113% | +$655K | ﹤0.01% | 628 |
|
|
2023
Q1 | $688K | Buy |
11,986
+2,134
| +22% | +$120K | ﹤0.01% | 667 |
|
|
2022
Q4 | $552K | Sell |
9,852
-133,137
| -93% | -$6.78M | ﹤0.01% | 697 |
|
|
2022
Q3 | $6.06M | Sell |
142,989
-4,908
| -3% | -$251K | 0.02% | 303 |
|
|
2022
Q2 | $7.99M | Buy |
147,897
+137,749
| +1,357% | +$8.27M | 0.02% | 244 |
|
|
2022
Q1 | $652K | Buy |
10,148
+2,905
| +40% | +$191K | ﹤0.01% | 566 |
|
|
2021
Q4 | $485K | Buy |
7,243
+2,400
| +50% | +$162K | ﹤0.01% | 634 |
|
|
2021
Q3 | $331K | Buy |
4,843
+100
| +2% | +$7.07K | ﹤0.01% | 658 |
|
|
2021
Q2 | $323K | Hold |
4,743
| – | – | ﹤0.01% | 678 |
|
|
2021
Q1 | $328K | Buy |
4,743
+178
| +4% | +$12.1K | ﹤0.01% | 641 |
|
|
2020
Q4 | $296K | Hold |
4,565
| – | – | ﹤0.01% | 641 |
|
|
2020
Q3 | $216K | Sell |
4,565
-30,960
| -87% | -$1.47M | ﹤0.01% | 709 |
|
|
2020
Q2 | $1.67M | Buy |
35,525
+18,378
| +107% | +$903K | 0.01% | 548 |
|
|
2020
Q1 | $766K | Sell |
17,147
-62
| -0.4% | -$3.25K | ﹤0.01% | 673 |
|
|
2019
Q4 | $1M | Hold |
17,209
| – | – | ﹤0.01% | 742 |
|
|
2019
Q3 | $1.03M | Sell |
17,209
-638
| -4% | -$38K | ﹤0.01% | 689 |
|
|
2019
Q2 | $997K | Buy |
17,847
+747
| +4% | +$38.5K | ﹤0.01% | 705 |
|
|
2019
Q1 | $953K | Sell |
17,100
-400
| -2% | -$20.4K | ﹤0.01% | 646 |
|
|
2018
Q4 | $789K | Sell |
17,500
-16,200
| -48% | -$889K | ﹤0.01% | 636 |
|
|
2018
Q3 | $2.22M | Sell |
33,700
-4,200
| -11% | -$261K | 0.01% | 375 |
|
|
2018
Q2 | $2.44M | Sell |
37,900
-1,600
| -4% | -$99.1K | 0.01% | 360 |
|
|
2018
Q1 | $2.19M | Sell |
39,500
-100
| -0.3% | -$5.24K | 0.01% | 388 |
|
|
2017
Q4 | $1.9M | Sell |
39,600
-13,500
| -25% | -$661K | 0.01% | 423 |
|
|
2017
Q3 | $2.68M | Sell |
53,100
-2,700
| -5% | -$139K | 0.01% | 379 |
|
|
2017
Q2 | $3.04M | Sell |
55,800
-200
| -0.4% | -$9.55K | 0.01% | 354 |
|
|
2017
Q1 | $2.36M | Sell |
56,000
-460
| -0.8% | -$19.7K | 0.01% | 452 |
|
|
2016
Q4 | $2.42M | Buy |
56,460
+4,060
| +8% | +$165K | 0.01% | 456 |
|
|
2016
Q3 | $2.16M | Buy |
+52,400
| New | +$2.2M | 0.01% | 421 |
|
|
2014
Q1 | – | Sell |
-191
| Closed | -$4K | – | 1332 |
|
|
2013
Q4 | $4K | Buy |
+191
| New | +$3.5K | ﹤0.01% | 1198 |
|
Other funds holding IART
RCMNY
PCMI
Bessemer Group's IART Position: Q2 2026 in Review
Bessemer Group increased its Integra LifeSciences (IART) stake by 207% in Q2 2026, buying an estimated $13.9K and bringing the position to 1,469 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #1908.
Bessemer Group first reported a position in IART in Q4 2013 and has held it in 41 quarters since. The position peaked at $7.99M in Q2 2022. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.
- Bessemer Group held 1,469 shares of Integra LifeSciences worth $26K as of Q2 2026.
- Bessemer Group bought 991 Integra LifeSciences shares in Q2 2026, an estimated $13.9K.
- Integra LifeSciences made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1908 holding.
- Bessemer Group first reported a position in Integra LifeSciences in Q4 2013 and has held it in 41 quarters since.
- Bessemer Group's Integra LifeSciences position peaked at $7.99M in Q2 2022.
- 213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.
Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.